SERPINB2 and prostate cancer: We have combined the cytotoxicity of an α-emitting radioisotope (213Bi) with the targeting potential of PAI2 to create the novel construct 213Bi-PAI2, a potential new therapeutic agent for targeted α therapy of breast and prostate cancer (Li et al, 2002b).